SMMT vs TLRY · $11.46B cap vs rev $915.5M
Summit Therapeutics PLC (SMMT) versus Tilray Inc (TLRY) — a side-by-side from cached financials, not a winner call.
Summit Therapeutics PLC (SMMT) is a biotechnology company listed on US.
Tilray Inc (TLRY) is a drug manufacturers - specialty & generic company listed on NASDAQ.
SMMT does not have a complete income-statement cache yet.
Latest reported TLRY revenue for 2026-05-31 was $915.5M. Net income was -$121.4M. Revenue was up 11.5% from 2025-05-31 to 2026-05-31. TLRY currently screens at market cap $573.9M.
SMMT currently screens at market cap $11.46B. TLRY currently screens at market cap $573.9M.
Not investment advice. Open the SMMT and TLRY stock pages for the full models.
Not investment advice.